Rapid Novor

Rapid Novor helps biotech and pharmaceutical companies extract the full potential of antibodies in ways never before possible.

New Project - 2024-12-16T165848.285

Antibody Sequencing

Monoclonal antibody sequencing from small protein samples, no need for hybridoma or DNA information. Full sequence in record time.

New Project - 2024-12-16T165848.285

Antibody Discovery

Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
New Project - 2024-12-16T165848.285

HDX-MS Epitope Mapping

Mass spectrometry-based epitope mapping. Epitope mapping to identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.

At Rapid Novor, we focus on the building blocks of life: proteins. Genomic technologies have had a profound impact, however the proteome is the real cellular machinery and it has become clear that a protein centric approach will be pivotal to the next decade of breakthroughs in precision medicine and immunotherapy. Antibodies help the immune system fight diseases, and they have immense utility in diagnostics and therapeutics. As they are constantly evolving, they are difficult to study and control without direct insight into the protein sequence, structure and other characteristics. At Rapid Novor, we are committed to helping people understand the immune system by directly accessing the functional, circulating proteins.

Applications

Antibody Engineering

Antibody Intellectual Property Protection

Hybridoma Loss Insurance

In Vitro Diagnostics

Biologics Drug Discovery

Target Validation

Gene & Cell Therapy Development

Veterinary Medicine and Research

Cell Line Development

Biosimilar Development

Featured Products

Coming Soon

Popular Research Areas

Coming Soon

Services Offered

More About Rapid Novor

Who is Rapid Novor?

Rapid Novor is the world leader in antibody protein sequencing technology and is home to the largest privately funded mass spectrometry proteomics facility in Canada. The team has over 20 years of experience specializing in proteomics, bioinformatics and Big Data processing and was the first to offer a commercial solution to distinguish between isoleucine and leucine (WILD®). Rapid Novor’s industry-leading REmAb® platform directly sequences antibody proteins, without needing access to the cell line.

Flyers and Product Guides

Coming Soon…

Coming Soon…

Latest Blogs

Need More Information?

The Krishgen support team strives to provide swift responses and resolution to your queries. Get in touch for a technical question, product query or quote request.

Contact Form Demo